Skip to main content
Mankind Pharma Limited logo

Mankind Pharma Limited — Investor Relations & Filings

Ticker · MANKIND ISIN · INE634S01028 LEI · 33580067G8AZ7S8NYA02 BSE.NS Manufacturing
Open in API
Filings indexed 397 across all filing types
Latest filing 2025-07-31 Regulatory Filings
Country IN India
Listing BSE.NS MANKIND

About Mankind Pharma Limited

https://www.mankindpharma.com/

Mankind Pharma Limited focuses on the development, manufacturing, and marketing of a broad spectrum of pharmaceutical formulations and consumer healthcare products. The company’s portfolio spans various therapeutic areas, including anti-infectives, cardiovascular, gastrointestinal, dermatology, and respiratory health. It maintains a significant presence in the over-the-counter segment with brands such as Manforce, Prega News, and Gas-O-Fast. The organization operates a robust research and development infrastructure dedicated to creating affordable and accessible medicinal solutions. Its operational model leverages an extensive distribution network to ensure product availability across diverse geographic regions, prioritizing high-quality healthcare delivery and patient-centric innovation.

Recent filings

Filing Released Lang Actions
Record Date
Regulatory Filings
2025-07-31 English
Integrated Filing- Financial
Regulatory Filings
2025-07-31 English
Outcome of Board Meeting
Regulatory Filings
2025-07-31 English
Dividend
Regulatory Filings
2025-07-31 English
Incorporation
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges informing about the incorporation of a wholly owned subsidiary company in Sri Lanka. It references compliance with SEBI Listing Obligations and Disclosure Requirements Regulations, specifically Regulation 30 & 51, which pertain to disclosure of material events and corporate actions. The document is dated July 24, 2025, and is signed by the Company Secretary and Compliance Officer. The content is an announcement of a corporate event (incorporation of a subsidiary) rather than a detailed financial report or management discussion. The document length is short (1761 characters), and it serves as an official notification to the stock exchanges rather than a full report. Therefore, it fits best under Regulatory Filings (RNS), which is the category for general regulatory announcements and compliance documents that do not fit other specific categories.
2025-07-24 English
General Updates
Major Shareholding Notification Classification · 95% confidence The document is a formal letter addressed to stock exchanges and the board of directors of Mankind Pharma Limited regarding a request for reclassification of shareholding from the 'Promoter and Promoter Group' category to the 'Public' category. It references Regulation 31A of the SEBI Listing Regulations, which governs shareholding classifications. The content focuses on shareholding category changes and related regulatory compliance, not on financial results, audit, or management reports. It is not a report itself but an official notification of a change in shareholding classification. This fits the category of Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels or classifications. The document length and detail support this classification with high confidence.
2025-07-22 English

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.